Evidence map›Paper›PMID 42166148›Full record

ArticlemAbs2026

Preclinical safety evaluation of the dipeptidyl peptidase 3 inhibiting antibody Procizumab in rodents and non-human primates.

Dirk van Lier, Magali Genest, Adrien Picod, Francesca Manicone, Bruno Garcia, Theo Ikenna Uba, Anika Schroeter, Karine Santos, Antoine Herpain, Alexis Nguyen and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dirk van LierDepartment of Intensive Care Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0002-9176-4852
Magali GenestParis Cité University, INSERM UMR-S 942, Cardiovascular Markers in Stress Condition (MASCOT), Paris, France.
Adrien PicodParis Cité University, INSERM UMR-S 942, Cardiovascular Markers in Stress Condition (MASCOT), Paris, France.
Francesca ManiconeExperimental Laboratory of Intensive Care, Université Libre de Bruxelles, Brussels, Belgium.
Bruno GarciaExperimental Laboratory of Intensive Care, Université Libre de Bruxelles, Brussels, Belgium.
Theo Ikenna Uba4TEEN4 Pharmaceuticals GmbH, Hennigsdorf, Germany.
Anika SchroeterDr. Anika Schroeter e.U, Vienna, Austria.
Karine Santos4TEEN4 Pharmaceuticals GmbH, Hennigsdorf, Germany.
Antoine HerpainExperimental Laboratory of Intensive Care, Université Libre de Bruxelles, Brussels, Belgium.
Alexis NguyenParis Cité University, INSERM UMR-S 942, Cardiovascular Markers in Stress Condition (MASCOT), Paris, France.
Feriel AzibaniParis Cité University, INSERM UMR-S 942, Cardiovascular Markers in Stress Condition (MASCOT), Paris, France.
Alexandre MebazaaParis Cité University, INSERM UMR-S 942, Cardiovascular Markers in Stress Condition (MASCOT), Paris, France.
Matthijs KoxDepartment of Intensive Care Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands.
Peter PickkersDepartment of Intensive Care Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cytosolic protease dipeptidyl peptidase 3 (DPP3) is released into the circulation upon profound cellular stress. In the bloodstream, circulating DPP3 (cDPP3) rapidly degrades several important mediators of vascular tone. The cDPP3-antagonizing antibody Procizumab (PCZ) improved outcome in animal models of shock. This study aimed to establish the safety and tolerability of PCZ across relevant animal species. In the first study, mice received vehicle (

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedDipeptidyl-Peptidases and Tripeptidyl-PeptidasesAnimalsDrug Evaluation, PreclinicalFemaleHumansMacaca fascicularisMaleMiceAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDipeptidyl-Peptidases and Tripeptidyl-PeptidasesDipeptidyl peptidase 3preclinicalprocizumab

Identifiers

PMID42166148
PMCPMC13196631

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.